A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke

European Journal of Neurology

Volumn 12, Issue 6, 2005, Pages 453-461

  Stamenova, P ^a   Koytchev, R ^b   Kuhn, K ^c   Hansen, Corinna ^c   Horvath, F ^d   Ramm, S ^e   Pongratz, D ^f  

^a UNIVERSITY HOSPITAL 'QUEEN GIOVANNA'   (Bulgaria)

^b CCDRD AG   (Germany)

^c Strathmann AG   (Germany)

^d PP Nature Balance Lizenz GmbH   (Germany)

^e Med Log RCR   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Placebo; Randomized controlled trial; Spasticity; Stroke; Tolperisone

Indexed keywords

TOLPERISONE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FRACTURE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE HYPERTONIA; NAUSEA; PARALLEL DESIGN; PODAGRA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SPASTICITY; STOMACH PAIN; THORAX PAIN; TREATMENT INDICATION; VOMITING;

AGED; CEREBROVASCULAR ACCIDENT; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; MUSCLE TONUS; TIME FACTORS; TOLPERISONE; TREATMENT OUTCOME;

EID: 20044367680     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01006.x     Document Type: Article

References (34)

1. Bakheit AMO, Thilmann AF, Ward AB et al. (2000). A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31:2402-2406.
2. Bass B, Weinshenker B, Rice GP et al. (1988). Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 15:15-19.
3. Bes A, Eyssette M, Pierrot-Deseilligny E, Rohmer F, Warter JM (1988). A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 10:709-718.
4. Bohannon RW, Smith MB (1987). Interrater reliability of a Modified Ashworth Scale of muscle spasticity. Phys Ther 67:206-207.
5. Dietz V (2001). Syndrom der spastischen Parese. Aktuelle Neurol 28:49-52.
6. Dulin J, Kovács L, Ramm S, Horvath F, Ebeling L, Kohnen R (1998). Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 31:137-142.
7. Emre P (1993). New development in the medical treatment of spasticity. In: Thilmann AF, Burke DJ, Rymer WZ, eds. Spasticity: Mechanisms and Management. Springer, Berlin, Heidelberg, New York, pp. 372-384.
8. Farkas S, Gere A (1994). Pharmacology of Tolperisone (Mydocalm). Studies on the Mechanism of Action. Gedeon Richter Ltd, Company Report RGD 47012.
9. Fehér M, Juvancz P, Szontagh M (1985). Effect of Mydocalm in the rehabilitation of hemiparesis. Balneológia Rehailitácio Gyógyfürdoügy 6:201-205.
10. Gracies JM, Elovic E, McGuire J, Simpson D (1997). Traditional pharmacological treatments for spasticity part II: general and regional treatments. Muscle Nerve Suppl 6:92-120.
11. Groves L, Shellenberger MK, Davis CS (1998). Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 15:241-251.
12. Haas BM, Bergström E, Jamous A, Bennie A (1996). The inter rater reliability of the original and of the modified Ashworth Scale for the assessment of spasticity in patients with spinal cord injury. Spinal Cord 34:560-564.
13. Haque A, Hossain M, Khan JK, Kuo H, Lambein F, De Reuck J (1994). New findings and symptomatic treatment for neurolathyrism, a motor neuron disease in north west Bangladesh. Paraplegia 32:570-572.
14. Hinderer SR, Lehmann JF, Price R, White O, DeLateur BJ, Deitz J (1990). Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments. Am J Phys Med Rehabil 69:311-317.
15. Hulme A, MacLennan WJ, Ritchie RT, John VA, Shotton PA (1985). Baclofen in the elderly stroke patient - its side-effects and pharmacokinetics. Eur J Clin Pharmacol 29:467-469.
16. Katz RT, Rovai GP, Brait C, Rymer WZ (1992). Objective quantification of spastic hypertonia: correlation with clinical findings. Arch Phys Med Rehabil 73:339-347.
17. Kohnen R, Krüger HP, Dulin J (1995). Die humanexperimentelle Untersuchung sedierender Wirkungen von Medikamenten im Zusammenwirken mit Alkohol. Psychologie 21:768-775.
18. Lataste X, Emre M, Davies C, Groves L (1994). Comparative profile of tizanidine in the management of spasticity. Neurology 44 (Suppl. 9):53-59.
19. Medici M, Pebet M, Ciblis D (1989). A double-blind, long-term study of tizanidine (Sirdalud) in spasticity due to cerebrovascular lesions. Curr Med Res Opin 11:398-407.
20. Melka A, Haimanot RT (1995). Tolperisone HCl (Mydocalm): A Randomized Doubleblind and Placebo Controlled Drug Trial. International Conference on Lathyrus and Lathyrism, Addis Adeba, Ethiopia, pp. 31-32 (Book of Abstracts).
21. Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM (2001). Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil 82:1155-1163.
22. Milanov IG (1992). Mechanisms of baclofen action on spasticity. Acta Neurol Scand 85:305-310.
23. Miskolczi P, Vereczkey L, Frenkl R (1987). Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavailability studies. J Pharm Biomed Anal 5:695-700.
24. O'Brien CF, Seeberger LC, Smith DB (1996). Spasticity after stroke. Epidemiology and optimal treatment. Drugs Aging 9:332-340.
25. Ogawa N, Asanuma M, Hirata H, Ota Z, Yamawaki Y, Yamamoto M (1992). Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease. J Int Med Res 20:78-86.
26. Ono H, Fukuda H, Kudo Y (1984). Mechanism of depressant action of muscle relaxants on spinal reflexes: participation of membrane stabilizing action. J Pharmacobiodyn 7:171-176.
27. Ono H, Matsumoto K, Kalo K et al. (1986). Effects of tizanidine, a centrally acting muscle relaxant, on motor systems. Gen Pharmacol 17:137-142.
28. Pratzel HG, Alken RG, Ramm S (1996). Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain 67:417-425.
29. Shah S, Vanclay F, Cooper B (1989). Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol 42:703-709.
30. Sloan RL, Sinclair E, Thompson J, Taylor S, Pentland B (1992). Inter-rater reliability of the modified Ash worth Scale for spasticity in hemiplegic patients. Int J Rehabil Res 15:158-161.
31. Stien R, Nordal HJ, Oftedal SI, Slettebo M (1987). The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 75:190-194.
32. The United Kingdom Tizanidine Trial Group (1994). A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 44 (Suppl. 9):70-78.
33. Wallace JD (1994). Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 44 (Suppl. 9):60-69.
34. Wissel J, Müller J, Dressnandt J et al. (2000). Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20:44-49.